This site is intended for healthcare professionals
News

Johnson & Johnson initiates Phase I/IIa trial of Ad26.COV2-S, recombinant, to treat COVID-19.

Read time: 1 mins
Last updated:12th Jun 2020
Published:12th Jun 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register free for full access to medthority.com